Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 7, 2007, Pages 455-461

  Ok, Hwa Jhee ^a   Hee, Kyoung Seo ^b,c   Min, Ho Lee ^c   Yong, Cheol Jeon ^c   Shaw, Leslie M ^d   Seung, Hoon Lee ^e   Hur, Yeon ^f   Kim, Kwang Hyun ^f   Lee, Heon Soo ^f   Seo, Eun Lee ^c   Ju, Seop Kang ^b,c  

^a Kongju National University   (South Korea)

^b Department of Biochemistry and Molecular Biology   (South Korea)

^c Hanyang University   (South Korea)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Korea Food and Drug Administration   (South Korea)

^f Bio Mediang Co   (South Korea)

Author keywords

Antidepressants; CAS 61869 08 7; Paroxetine, bioequivalence study, liquid chromatography tandem mass spectrometry, pharmacokinetics

Indexed keywords

ACETONITRILE; AMMONIUM FORMATE; ETHER; FLUOXETINE; METHYL CHLORIDE; PAROXETINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; NORMAL HUMAN; TANDEM MASS SPECTROMETRY;

EID: 34547801215     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296631     Document Type: Article

References (25)

1. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetinetreatment response in late-life depression. Neuropsychopharmacology. 2000;23:587-590.
2. Kaye CM, haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;350 Suppl:60-75.
3. Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, et al. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol. 2004;44:1352-1359.
4. rd, Mulsant BH, Pollock BG. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. J Clin Psychiatr. 1999;60:21-25.
5. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002;62:655-703.
6. Boyer WF, Feighner JP. An overview of paroxetine. J Clin Psychiatry. 1992;53:3-6.
7. Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky, L et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Adolesc Psychiatry. 1999;38:952-959.
8. Sindrup SH, Brosen K, Gram LF, Hallas J, Skjelbo E, Allen A, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992; 51:278-287.
9. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphoism. Clin Pharmacol Ther. 1992;51:288-295.
10. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol. 2004;60:553-557.
11. Nemeroff CB. Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 1993;13:10S-17S.
12. Eap CB, Bouchoux G, Amey M, Cochard N, Savary L, Baumann P. Simultaneous determination of human plasma levels of citralopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. J Chromatogr Sci. 1998;36:365-371.
13. Mauer HH, Bickeboeller-Friedrich J. Screening procedure for the detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. J Anal Toxicol. 2000;24:340-347.
14. Leis HJ, Windischhofer W, Raspotnig G, Fauler S. Stable isotope dilution negative ion chemical ionization gas chromatography-mass spectrometry for the quantitative analysis of paroxetine in human plasma. J Mass Spectrom. 2001;36:923-928.
15. Leis HJ, Windischhofer W, Fauler G. Improved sample preparation for the quantitative analysis of paroxetine in human plasma by stable isotope dlution negative ion chemical ionization gas chromatography-mass spectrometry. J Chromatogr B. 2002;779:353-357.
16. Erk N, Biryol I. Voltammetric and HPLC techniques for the determination of paroxetine hydrochloride. Pharmazie. 2003;58:699-704.
17. Lopez-Calull C, Dominguez N. Determination of paroxetine in plasma by high-performance liquid chromatography for bioequivalence studies. J Chromatogr B Biomed Sci Appl. 1999;724:393-398.
18. Zhu Z, Neirinck L. High-performance liquid chromatography-mass spectrometry method for the determination of paroxetine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;780:295-300.
19. Guidance for Industry: Bioanalytical method validation, USDHHS, FDA, CDER, CVM; 2001.
20. Hyder AA, Human D, Crawley F, IJesselmuiden C, Singer PA, Benatar SR. Revised Declaration of Helsinki. Br Med J. 2001;323:283-283.
21. Shargel I, Yu-Pong S, Yu A. Applied biopharmaceutics and pharmacokinetics: 15. Bioavailability and bioequivalence, 5th Ed., pp 453 New York, McGraw Hill, USA; 2005.
22. Chen M, Shah V, Patnaik R, Adams W, Hussain A, Conner D, et al. Bioavailability and Bioequivalence: An FDA Regulatory Overview. Pharm Res. 2001;18:1645-1650.
23. Guidance for industry: Statistical approaches to establishing bioequivalence, USDHHS, FDA, CDER, CVM; 2001.
24. Federal Register part 320, Bioavailability and bioequivalence requirements. 2002;67:244.
25. Massaroti P, Cassiano NM, Duarte LF, Campos DR, Marchioretto MA, Bernasconi G, et al. Validation of a selective method for determination of paroxetine in human plasma by LC-MS/MS. J Pharm Pharm Sci. 2005;17:340-347.